Core Viewpoint - EuroEyes International Eye Clinic Limited announced the resignation of Dr. Markus Braun as Executive Director and Chief Financial Officer, effective September 14, 2025, due to his career development plans. Marcus Huascar Bracklo has been appointed as the new Executive Director and CFO, effective the same date [3][7][8]. Group 1: Resignation and Appointment - Dr. Markus Braun will resign from his positions as Executive Director and CFO, and will no longer serve as the authorized representative under the Hong Kong Stock Exchange rules and the Companies Ordinance, effective September 14, 2025 [3][6]. - The board has appointed Marcus Huascar Bracklo as the new Executive Director and CFO, effective September 14, 2025. Bracklo has been with the company since July 2012 and has served as a non-executive director since March 2019 [8][10]. Group 2: Background of Marcus Huascar Bracklo - Bracklo has over 25 years of experience in the medical field, specializing in corporate finance, accounting, and mergers and acquisitions. He has held significant positions at various firms, including being a partner at Arthur Andersen and serving as Managing Director at Sal. Oppenheim [4][9]. - He holds a Bachelor's degree in Economics from University College London and a Master's degree in Economics from the London School of Economics. He is a Chartered Accountant in the UK and a certified auditor in Germany [4][9]. Group 3: Board's Confidence - The board believes that Bracklo's expertise and familiarity with the company's operations will positively contribute to the strategic and financial development of EuroEyes [10].

Core Viewpoint - Dr. Markus Braun has resigned as Executive Director and Chief Financial Officer of 德视佳 (01846) due to personal career development plans, effective September 14, 2025 [1] Group 1: Management Changes - Dr. Markus Braun will no longer serve as the company's authorized representative under the Hong Kong Stock Exchange Listing Rules and the Companies Ordinance from September 14, 2025 [1] - Mr. Marcus Huascar Bracklo has been appointed as Executive Director and Chief Financial Officer, effective September 14, 2025 [1] - Following the appointment, Mr. Bracklo will no longer be a member of the Audit Committee, and independent non-executive director Katherine Rong Xin will join the Audit Committee [1] Group 2: Audit Committee Composition - The Audit Committee will include Philip Duncan Wright (Chairman), Hans Helmuth Hennig, and Katherine Rong Xin after the changes effective September 14, 2025 [1] - Mr. Bracklo will be appointed as the authorized representative under the Listing Rules and the Companies Ordinance, as well as the agent for receiving legal documents, to fill Dr. Braun's vacancy [1]

Core Viewpoint - Dr. Markus Braun has resigned as Executive Director and Chief Financial Officer of 德视佳 (01846.HK) due to personal career development plans, effective September 14, 2025 [1] Group 1 - The company announced the resignation of Dr. Markus Braun from his positions, including as the authorized representative under listing rules and as the legal representative for company regulations [1] - Mr. Marcus Huascar Bracklo has been promoted from Non-Executive Director to Executive Director and appointed as Chief Financial Officer, effective September 14, 2025 [1]

Hans Helmuth Hennig先生 Katherine Rong Xin女士 Philip Duncan Wright先生 本公司設立三個董事委員會。下表載列各董事於該等委員會擔任的職務的資料， 由2025年9月14日起生效。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 董事名單與其角色和職能 德視佳國際眼科有限公司（「本公司」）董事（「董事」）會（「董事會」）成員載列如 下，由2025年9月14日起生效： 執行董事 Jørn Slot Jørgensen醫生 （主席） Jannik Jonas Slot Jørgensen先生 Dan Zoltan Reinstein教授 Marcus Huascar Bracklo先生 獨立非執行董事 | 董事委員會 | | | | | --- | --- | --- | --- | | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | Jørn Slot Jørgensen醫生 | | M | C | | Jannik Jonas ...

Group 1 - Dr. Markus Braun has resigned as Executive Director and Chief Financial Officer of 德视佳 (01846) due to personal career development plans, effective from September 14, 2025 [1] - Mr. Marcus Huascar Bracklo has been appointed as Executive Director and Chief Financial Officer, effective from September 14, 2025 [1] - Following the appointment, Mr. Bracklo will no longer be a member of the Audit Committee, and independent non-executive director Ms. Katherine Rong Xin will join the Audit Committee [1] Group 2 - The Audit Committee will consist of Mr. Philip Duncan Wright (Chairman), Mr. Hans Helmuth Hennig, and Ms. Xin, effective from September 14, 2025 [1] - Mr. Bracklo will also serve as the authorized representative under the Listing Rules and the Companies Ordinance, filling Dr. Braun's vacancy [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） (1) 執行董事兼首席財務官辭任； (2) 執行董事調任及委任首席財務官； (3) 審核委員會組成之變更；及 EuroEyes International Eye Clinic Limited (4) 上市規則授權代表及公司條例授權代表及 法律程序文件代理人之變更 (1) 執行董事兼首席財務官辭任 德視佳國際眼科有限公司（「本公司」，連同其附屬公司，統稱為「本集團」）董 事（「董事」）會（「董事會」）宣佈，因彼本身的職業發展規劃，Markus Braun博 士（「Braun博士」）已提出辭任本公司執行董事兼首席財務官（「首席財務官」） 並將不再擔任(i)香港聯合交易所有限公司證券上市規則（「上市規則」）第3.05 條項下之本公司授權代表（「上市規則授權代表」）；及(ii)根據香港法例第622 章公司條例第16部代表本公司於香 ...

德视佳(01846.HK)拟8月28日举行董事会会议以审批中期业绩 德视佳(01846.HK)获Jørgensen Jannik Jonas Slot增持11.8万股 格隆汇8月15日丨德视佳(01846.HK)公告，公司将于2025年8月28日(星期四)举行董事会会议，以(其中包 括)(i)审阅及批准公司及其附属公司截至2025年6月30日止6个月中期业绩及其刊发；(ii)考虑建议派付中 期股息(如适用)；及(iii)处理任何其他事务。 相关事件 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 EuroEyes International Eye Clinic Limited 德視佳國際眼科有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1846） 於本公告日期，董事會包括執行董事Jørn Slot Jørgensen醫生、Markus Braun 博士、Jannik Jonas Slot Jørgensen先生及Dan Zoltan Reinstein教授；非執行董 事Marcus Huascar Bracklo先生；獨立非執行董事Hans Helmuth Hennig先生、 Katherine Rong Xin女士及Philip Duncan Wright先生。 德視佳國際眼科有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本 公司將於2025年8月28日（星期四）舉行董事會會議，以（其中包括）(i)審閱及批准 本公司及其附屬公司截至2025年6月30日止六個月之中期 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 德視佳國際眼科有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01846 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 1,000,000,000 | USD | | 0.01 | USD | | 10,000,000 | 本月底法定/註冊股 ...

Financial Performance - Revenue for 2024 reached HKD 715,682,000, a slight increase from HKD 714,289,000 in 2023[7] - Gross profit decreased to HKD 286,593,000, resulting in a gross margin of 40.0%, down from 47.0% in the previous year[7] - Net profit for the year was HKD 84,359,000, reflecting a net profit margin of 11.8%, compared to 18.7% in 2023[7] - Adjusted net profit after tax was HKD 100,334,000, with an adjusted net profit margin of 14.0%[7] - The company reported an adjusted profit attributable to owners of HKD 98,260,000, down from HKD 139,705,000 in 2023[7] - EBITDA fell by 18.8% to HKD 228.0 million, with adjusted EBITDA down 16.8% to HKD 240.5 million, reflecting the impact of new clinic costs[19] - Net profit attributable to equity holders decreased by 37.3% to HKD 82.3 million, largely due to additional costs from new clinics[19] - The total revenue for the fiscal year reached HKD 715.7 million, a year-on-year increase of 0.2%, primarily driven by strong growth in presbyopia cataract surgeries in Germany, China, and the UK[32] Revenue Breakdown - The company achieved a record revenue of HKD 715.7 million for the fiscal year 2024, up from HKD 714.3 million in 2023, with contributions from Germany, China, Denmark, and the UK being approximately HKD 385.2 million, HKD 145.5 million, HKD 71.6 million, and HKD 113.4 million respectively[13][14][18]. - Revenue from presbyopia treatment increased to HKD 390.8 million, representing a 5% growth compared to the previous year, and accounted for 54.6% of total revenue[14][17][18]. - In Germany, total revenue grew by 1% to HKD 385.2 million, driven by a 2.6% increase in revenue from lens replacement surgeries[14][20]. - The UK revenue rose by 12% to HKD 113.4 million, supported by the opening of the flagship Laser Eye Clinic in Knightsbridge, which focused on presbyopia treatment[14][20]. - In China, despite a significant drop in consumer confidence, revenue from lens replacement surgeries increased by 1% to HKD 145.5 million, offsetting declines in other treatment areas[15][19]. Cost and Expenses - The company's gross profit decreased by 14.6% to HKD 286.6 million, primarily due to the fixed costs of new clinics and inflation-related salary increases[18][19]. - Total cost of revenue increased by 13.3% to HKD 429.1 million in 2024, primarily due to higher employee benefits and depreciation of property, plant, and equipment[35]. - Selling expenses rose by 10.8% to approximately HKD 80.8 million, representing 11.3% of total revenue, compared to 10.2% in the previous year[37]. - Administrative expenses increased by 29.6% to approximately HKD 115.7 million, accounting for 16.2% of total revenue, up from 12.5% in 2023[39]. Strategic Focus and Expansion - The company aims to focus on profitable treatments, particularly for myopia and presbyopia, while controlling costs to achieve rapid breakeven[12]. - The company plans to enhance its focus on presbyopia treatments through lens replacement surgeries[12]. - The company plans to continue its expansion strategy in Europe and Asia, targeting new markets through acquisitions by 2025[15][17]. - The company opened four new clinics during the fiscal year, which contributed an impact of HKD 43.8 million to net profit[19]. - New flagship clinics in Hong Kong and London have exceeded expectations, with emerging clinics in mainland China also performing well[29]. Management and Governance - The company has a strong management team with extensive experience in ophthalmology and financial management, enhancing operational oversight in various regions[88][91]. - The company emphasizes the importance of its management team, noting that the loss of key personnel could impact operations and incur additional costs[103]. - The company has established a compensation committee to review the remuneration policies for directors and senior management based on performance and market practices[125]. Shareholder Information - The company reported a proposed final dividend of HKD 0.0297 per ordinary share, totaling approximately HKD 9,524,968, subject to approval at the upcoming annual general meeting[97]. - As of December 31, 2024, the distributable reserves available for shareholders amount to HKD 981,352,000, down from HKD 1,042,276,000 in 2023[118]. - The company’s dividend policy will be reviewed periodically by the board, considering factors such as financial performance and capital needs[100]. Risks and Compliance - The company faces risks related to economic instability, which could affect demand for its vision correction services[104]. - The company’s operations are compliant with relevant laws and regulations in Germany, Denmark, the UK, China, the Cayman Islands, and Hong Kong[110]. - The company has not been aware of any serious violations of employee-related laws and regulations that would significantly impact its operations[124]. Environmental and Social Responsibility - The company has implemented various environmental protection measures to reduce energy consumption, supported by its employees[108]. - The company has been involved in humanitarian efforts related to cataract surgery in countries such as China, Myanmar, and Nepal[89]. - The company is committed to delivering high-quality services and actively seeks customer feedback through patient surveys[113].